Evaluation of therapy of X-linked adrenoleukodystrophy

Neurochemical Research

Volumn 29, Issue 5, 2004, Pages 1003-1016

  Moser, Hugo W ^a,b   Fatemi, Ali ^a,b   Zackowski, Kathleen ^a,b   Smith, Seth ^a,b   Golay, Xavier ^a,b   Muenz, Larry ^c   Raymond, Gerald ^a,b  

^a KENNEDY KRIEGER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c WESTAT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; LORENZO OIL; MEVINOLIN; PLACEBO; TRIOLEIN; UBIDECARENONE;

ADRENOLEUKODYSTROPHY; BIOSTATISTICS; BONE MARROW TRANSPLANTATION; BRAIN CORTEX; CERVICAL SPINE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DIET THERAPY; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; GENE EXPRESSION; GENE MUTATION; HUMAN; LOW FAT DIET; MASS SPECTROMETRY; MOTOR PERFORMANCE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; RATING SCALE; REVIEW; SAMPLE SIZE; SCORING SYSTEM; SENSORY EVALUATION; X CHROMOSOME LINKED DISORDER; EVALUATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY;

ADRENOLEUKODYSTROPHY; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; MULTICENTER STUDIES; PLACEBOS;

EID: 3142688107     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NERE.0000021245.12181.90     Document Type: Review

References (115)

1. Igarashi, M., Schaumburg, H. H., Powers, J., Kishmoto, Y., Kolodny, E., and Suzuki, K. 1976. Fatty acid abnormality in adrenoleukodystrophy. J. Neurochem. 26:851-860.
2. Moser, H. W., Moser, A. B., Kawamura, N., Murphy, J., Suzuki, K., Schaumburg, H., and Kishimoto, Y. 1980. Adrenoleukodystrophy: elevated C26 fatty acid in cultured skin fibroblasts. Ann. Neurol. 7:542-549.
3. Moser, H. W., Moser, A. B., Frayer, K. K., Chen, W., Schulman, J. D., O'Neill, B. P., and Kishimoto, Y. 1981. Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids. Neurology 31:1241-1249.
4. Tsuji, S., Suzuki, M., Ariga, T., Sekine, M., Kuriyama, M., and Miyatake, T. 1981. Abnormality of long-chain fatty acids in erythrocyte membrane sphingomyelin from patients with adrenoleukodystrophy. J. Neurochem. 36:1046-1049.
5. Mosser, J., Douar, A. M., Sarde, C. O., Kioschis, P., Feil, R., Moser, H., Poustka, A. M., Mandel. J. L., and Aubourg, P. 1993. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 361:726-730.
6. Brown, F. R. 3rd, Van Duyn, M. A., Moser, A. B., Schulman, J. D., Rizzo, W. B., Snyder, R. D., Murphy, J. V., Kamoshita, S., Migeon, C. J., and Moser, H. W. 1982. Adrenoleukodystrophy: effects of dietary restriction of very long chain fatty acids and of administration of camitine and clofibrate on clinical status and plasma fatty acids. Johns Hopkins Med. J. 151:164-172.
7. Shapiro, E., Krivit, W., Lockman, L., Jambaque, I., Peters, C., Cowan, M., Harris, R., Blanche, S., Bordigoni, P., Loes, D., Ziegler, R., Crittenden, M., Ris, D., Berg, B., Cox, C., Moser, H., Fischer, A., and Aubourg, P. 2000. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 356:713-718.
8. Bezman, L., Moser, A. B., Raymond, G. V., Rinaldo, P., Watkins, P. A., Smith, K. D., Kass, N. E., and Moser, H. W. 2001. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann. Neurol. 49:512-517.
9. Bezman, L. and Moser, H. W. 1998. Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes. Am. J. Med. Genet. 76:415-119.
10. Higgins, C. F. 1992. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 8:67-113.
11. Kemp, S., Pujol, A., Waterham, H. R., van Geel, B. M., Boehm, C. D., Raymond, G. V., Cutting, G. R., Wanders, R. J., and Moser, H. W. 2001. ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum. Mutat. 18:499-515.
12. Lombard-Platet, G., Savary, S.. Sarde, C. O., Mandel, J. L., and Chimini, G. 1996. A close relative of the adrenoleukodystrophy (ALD) gene codes for a peroxisomal protein with a specific expression pattern. Proc. Natl. Acad. Sci. USA 93:1265-1269.
13. Dean, M., Hamon, Y., and Chimini, G. 2001. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 42:1007-1017.
14. Broccardo, C., Troffer-Charlier, N., Savary, S., Mandel, J. L., and Chimini, G. 1998. Exon organisation of the mouse gene encoding the adrenoleukodystrophy related protein (ALDRP). Eur. J. Hum. Genet. 6:638-641.
15. Netik, A., Forss-Petter, S., Holzinger, A., Molzer, B., Unterrainer, G., and Berger, J. 1999. Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy. Hum. Mol. Genet. 8:907-913.
16. Braiterman, L. T., Zheng, S., Watkins, P. A., Geraghty, M. T., Johnson, G., McGuinness, M. C., Moser, A. B., and Smith, K. D. 1998. Suppression of peroxisomal membrane protein defects by peroxisomal ATP binding cassette (ABC) proteins. Hum. Mol. Genet. 7:239-247.
17. Smith, K. D., Kemp, S., Braiterman, L. T., Lu, J. F., Wei, H. M., Geraghty, M., Sterten, G., Bergin, J. S., Pevsner, J., and Watkins, P. A. 1999. X-linked adrenoleukodystrophy: genes, mutations, and phenotypes. Neurochem. Res. 24:521-535.
18. Liu, L. X., Janvier, K., Berteaux-Lecellier, V., Cartier, N., Benarous, R., and Aubourg, P. 1999. Homo- and heterodimerization of peroxisomal ATP-binding cassette half-transporters. J. Biol. Chem. 274:32738-32743.
19. Moser, H. W., Smith, K. D., Watkins, P. A., Powers, J., and Moser, A. B. 2000. X-linked adrenoleukodystrophy. Pages 3257-3301, in Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valle, D. (eds.), The metabolic and molecular bases of inherited disease. McGraw Hill, New York.
20. Moser, A. B., Kreiter, N., Bezman, L., Lu, S., Raymond, G. V., Naidu, S., and Moser, H. W. 1999. Plasma very-long-chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann. Neurol. 45:100-110.
21. Ho, J. K., Moser, H., Kishimoto, Y., and Hamilton, J. A. 1995. Interactions of a very-long-chain fatty acid with model membranes and serum albumin. Implications for the pathogenesis of adrenoleukodystrophy. J. Clin. Invest. 96:1455-1463.
22. Whitcomb, R. W., Linehan, W. M., and Knazek, R. A. 1988. Effects of long-chain, saturated fatty acids on membrane microviscosity and adrenocorticotropin responsiveness of human adrenocortical cells in vitro. J. Clin. Invest. 81:185-188.
23. Knazek, R. A., Rizzo, W. B., Schulman, J. D., and Dave, J. R. 1983. Membrane microviscosity is increased in the erythrocytes of patients with adrenoleukodystrophy and adrenomyeloneuropathy. J. Clin. Invest. 72:245-248.
24. Choi, J. K., Ho, J., Curry, S., Qin, D., Bittman, R., and Hamilton, J. A. 2002. Interactions of very-long-chain saturated fatty acids with serum albumin. J. Lipid Res. 43:1000-1010.
25. Dubois-Dalcq, M., Feigenbaum, V., and Aubourg, P. 1999. The neurobiology of X-linked adrenoleukodystrophy, a demyelinating peroxisomal disorder. Trends Neurosci. 22:4-12.
26. McGuinness, M. C., Zhang, H. P., and Smith, K. D. 2001. Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy. Mol. Genet. Metab. 74: 256-263.
27. McGuinness, M. C., Lu, J. F., Zhang, H. P., Dong, G. X., Heinzer, A. K., Watkins, P. A., Powers, J., and Smith, K. D. 2003. Role of ALDP (ABCD1) and mitochondria in X-linked adrenoleukodystrophy. Mol. Cell. Biol. 23:744-753.
28. Schaumburg, H. H., Powers, J. M., Raine, C. S., Suzuki, K., and Richardson, E. P. Jr 1975. Adrenoleukodystrophy. A clinical and pathological study of 17 cases. Arch. Neurol. 32:577-591.
29. Powers, J. M., Liu, Y., Moser, A. B., and Moser, H. W. 1992. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J. Neuropathol. Exp. Neurol. 51:630-643.
30. Ito, M., Blumberg, B. M., Mock, D. J., Goodman, A. D., Moser, A. B., Moser, H. W., Smith, K. D., and Powers, J. M. 2001. Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. J. Neuropathol. Exp. Neurol. 60:1004-1019.
31. Igarashi, M., Belchis, D., and Suzuki, K. 1976. Brain gangliosides in adrenoleukodystrophy. J. Neurochem. 27:327-328.
32. Bizzozero, O. A., Zuniga, G., and Lees, M. B. 1991. Fatty acid composition of human myelin proteolipid protein in peroxisomal disorders. J. Neurochem. 56:872-878.
33. Kannagi, R., Nudelman, E., and Hakomori, S. 1982. Possible role of ceramide in defining structure and function of membrane glycolipids. Proc. Natl. Acad. Sci. USA 79:3470-3474.
34. Tagawa, Y., Laroy, W., Nimrichter, L., Fromholt, S. E., Moser, A. B., Moser, H. W., and Schnaar, R. L. 2002. Anti-ganglioside antibodies bind with enhanced affinity to gangliosides containing very long chain fatty acids. Neurochem. Res. 27:847-855.
35. Singh, I., Moser, A. E., Moser, H. W., and Kishimoto, Y. 1984. Adrenoleukodystrophy: impaired oxidation of very-long-chain fatty acids in white blood cells, cultured skin fibroblasts, and amniocytes. Pediatr. Res. 18:286-290.
36. Singh, I., Moser, A. E., Goldfischer, S., and Moser, H. W. 1984. Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy. Proc. Natl. Acad. Sci. USA 81:4203-4207.
37. Hashimoto, T. 1996. Peroxisomal beta-oxidation: enzymology and molecular biology. Ann. N. Y. Acad. Sci. 804:86-98.
38. Lazo, O., Contreras, M., Hashmi, M., Stanley, W., Irazu, C., and Singh, I. 1988. Peroxisomal lignoceroyl-CoA ligase deficiency in childhood adrenoleukodystrophy and adrenomyeloneuropathy. Proc. Natl. Acad. Sci. U. S. A. 85:7647-7651.
39. Wanders, R. J., van Roermund, C. W., van Wijland, M. J., Schutgens, R. B., van den Bosch, H., Schram, A. W., and Tager, J. M. 1988. Direct demonstration that the deficient oxidation of very-long-chain fatty acids in X-linked adrenoleukodystrophy is due to an impaired ability of peroxisomes to activate very long chain fatty acids. Biochem. Biophys. Res. Commun. 153:618-624.
40. Watkins, P. A.. Pevsner, J., and Steinberg, S. J. 1999. Human very-long-chain acyl-CoA synthetase and two human homologs: initial characterization and relationship to fatty acid transport protein. Prostaglandins Leukot. Essent. Fatty Acids 60:323-328.
41. Uchiyama, A., Aoyama, T., Kamijo, K., Uchida, Y., Kondo, N., Orii, T., and Hashimoto, T. 1996. Molecular cloning of cDNA encoding rat very-long-chain acyl-CoA synthetase. J. Biol. Chem. 271:30360-30365.
42. Heinzer, A. K., Kemp, S., Lu, J. F., Watkins, P. A., and Smith, K. D. 2002. Mouse very-long-chain acyl-CoA synthetase in X-linked adrenoleukodystrophy. J. Biol. Chem. 277:28765-28773.
43. McGuinness, M. C., Powers, J. M., Bias, W. B., Schmeckpeper, B. J., Segal, A. H., Gowda, V. C., Wesselingh, S. L., Berger, J., Griffin, D. E., and Smith, K. D. 1997. Human leukocyte antigens and cytokine expression in cerebral inflammatory demyelinative lesions of X-linked adrenoleukodystrophy and multiple sclerosis. J. Neuroimmunol. 75:174-182.
44. Lu, J. F., Lawler, A. M., Watkins, P. A., Powers, J. M., Moser, A. B., Moser, H. W., and Smith, K. D. 1997. A mouse model for X-linked adrenoleukodystrophy. Proc. Natl. Acad. Sci. U. S. A. 94:9366-9371.
45. Braiterman, L. T., Watkins, P. A., Moser, A. B., and Smith, K. D. 1999. Peroxisomal very-long-chain fatty acid beta-oxidation activity is determined by the level of adrenodeukodystrophy protein (ALDP) expression. Mol. Genet. Metab. 66:91-99.
46. Cartier, N., Guidoux, S., Rocchiccioli, F., and Aubourg, P. 2000. Simvastatin does not normalize very-long-chain fatty acids in adrenoleukodystrophy mice. FEBS Lett. 478:205-208.
47. Kemp, S., Wei, H. M., Lu, J. F., Braiterman, L. T., McGuinness, M. C., Moser, A. B., Watkins, P. A., and Smith, K. D. 1998. Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nat. Med. 4:1261-1268.
48. Steinberg, S. J., Kemp, S., Braiterman, L. T., and Watkins, P. A. 1999. Role of very-long-chain acyl-coenzyme A synthetase in X-linked adrenoleukodystrophy. Ann. Neurol. 46:409-412.
49. van Geel, B. M., Bezman, L., Loes, D. J., Moser, H. W., and Raymond, G. V. 2001. Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann. Neurol. 49: 186-194.
50. Moser, H. W. 1997. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 120:1485-1508.
51. Powers, J. M., DeCiero, D. P., Ito, M., Moser, A. B., and Moser, H. W. 2000. Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J. Neuropathol. Exp. Neurol. 59:89-102.
52. Powers, J. M., DeCiero, D. P., Cox, C., Richfield, E. K., Ito, M., Moser, A. B., and Moser, H. W. 2001. The dorsal root ganglia in adrenomyeloneuropathy: neuronal atrophy and abnormal mitochondria. J. Neuropathol. Exp. Neurol. 60:493-501.
53. Moser, H. W., Moser, A. B., Naidu, S., and Bergin, A. 1991. Clinical aspects of adrenoleukodystrophy and adrenomyeloneuropathy. Dev. Neurosci. 13:254-261.
54. Fatemi, A., Barker, P. B., Ulug, A. M., Nagae-Poetscher, L. M., Beauchamp, N. J., Moser, A. B., Raymond, G. V., Moser, H. W., and Naidu, S. 2003. MRI and proton MRSI in women heterozygous for X-linked adrenoleukodystrophy. Neurology 60: 1301-1307.
55. Berger, J., Molzer, B., Fae, I., and Bemheimer, H. 1994. X-linked adrenoleukodystrophy (ALD): a novel mutation of the ALD gene in 6 members of a family presenting with 5 different phenotypes. Biochem. Biophys. Res. Commun. 205:1638-1643.
56. Moser, H. W., Moser, A. B., Smith, K. D., Bergin, A., Borel, J., Shankroff, J., Stine, O. C., Merette, C., Ott, J., Krivit, W., and et al. 1992. Adrenoleukodystrophy: phenotypic variability and implications for therapy. J. Inherit. Metab. Dis. 15:645-664.
57. Maestri, N. E. and Beaty, T. H. 1992. Predictions of a 2-locus model for disease heterogeneity: application to adrenoleukodystrophy. Am. J. Med. Genet. 44:576-582.
58. Smith, K. D., Sack, G., and Beaty, T. et al. 1991. A genetic basis for the multiple phenotypes of X-linked adrenoleukodystrophy. Am. J. Hum. Genet. 49:165.
59. Aubourg, P., Blanche, S., Jambaque, I., Rocchiccioli, F., Kalifa, G., Naud-Saudreau, C.. Rolland, M. O., Debre, M., Chaussain, J. L., Griscelli, C., and et al. 1990. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N. Engl. J. Med. 322: 1860-1866.
60. Krivit, W., Lockman, L. A., Watkins, P. A., Hirsch, J., and Shapiro, E. G. 1995. The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. J. Inherit. Metab. Dis. 18:398-412.
61. Krivit, W., Peters, C., and Shapiro, E. G. 1999. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr. Opin. Neurol. 12:167-176.
62. Moser, H. W., Loes, D. J., Melhem, E. R., Raymond, G. V., Bezman, L., Cox, C. S., and Lu, S. E. 2000. X-Linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients. Neuropediatrics 31:227-239.
63. Pujol, A., Hindelang, C., Callizot, N., Bartsch, U., Schachner, M., and Mandel, J. L. 2002. Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum. Mol. Genet. 11:499-505.
64. Singh, I., Pahan, K., and Khan, M. 1998. Lovastatin and sodium phenylacetate normalize the levels of very-long-chain fatty acids in skin fibroblasts of X-adrenoleukodystrophy. FEBS Lett. 426:342-346.
65. Pai, G. S., Khan, M., Barbosa, E., Key, L. L., Craver, J. R., Cure, J. K., Betros, R., and Singh, I. 2000. Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients. Mol. Genet. Metab. 69:312-322.
66. Stanislaus, R., Pahan, K., Singh, A. K., and Singh, I. 1999. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci. Lett. 269:71-74.
67. Kwak, B., Mulhaupt, F., Myit, S.. and Mach, F. 2000. Stains as a newly recognized type of immunomodulator. Nat. Med. 6: 1399-1402.
68. Weinhofer, I., Forss-Petter, S., Zigman, M., and Berger, J. 2002. Cholesterol regulates ABCD2 expression: implications for the therapy of X-linked adrenoleukodystrophy. Hum. Mol. Genet. 11:2701-2708.
69. Koc, O. N., Day, J., Nieder, M., Gerson, S. L., Lazarus, H. M., and Krivit, W. 2002. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant. 30:215-222.
70. Hickey, W. F. and Kimura, H. 1988. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 239:290-292.
71. Hickey, W. F., Vass, K., and Lassmann, H. 1992. Bone marrow-derived elements in the central nervous system: an immunohistochemical and ultrastructural survey of rat chimeras. J. Neuropathol. Exp. Neurol. 51:246-256.
72. Forss-Petter, S., Werner, H., Berger, J., Lassmann, H., Molzer, B., Schwab, M. H., Bernheimer, H., Zimmermann, F., and Nave, K. A. 1997. Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice. J. Neurosci. Res. 50:829-843.
73. Kobayashi, T., Shinnoh, N., Kondo, A., and Yamada, T. 1997. Adrenoleukodystrophy protein-deficient mice represent abnormality of very-long-chain fatty acid metabolism. Biochem. Biophys. Res. Commun. 232:631-636.
74. Kurtzke, J. F. 1983. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452.
75. Koehler, W. and Sokolowski, P. 1999. A new disease-specific scoring system for adult phenotypes of X-linked adrenoleukodystrophy. J. Mol. Neurosci. 13:247-252.
76. Fischer, J. S., Rudick, R. A., Cutter, G. R., and Reingold, S. C. 1999. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult. Scler. 5:244-250.
77. Shapiro, E. G., Lockman, L. A., Balthazor, M., and Krivit, W. 1995. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J. Inherit. Metab. Dis. 18:413-129.
78. Denckla, M. B. 1985. Revised neurological examination for subtle signs (1985). Psychopharmacol. Bull. 21:773-800.
79. van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Scheuten, H. J., and van Gijn, J. 1988. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604-607.
80. Landgraf, J. M., Abetz, L., and Ware, J. E. 2000. Child Health Questionnaire. In The CHQ Users Manual. Healthact, Boston.
81. The Canadian Burden of Illness Study Group. 1998. Burden of illness of multiple sclerosis: part II: quality of life. Can. J. Neurol. Sci. 25:31-38.
82. Cohen, J. 1997. Statistical power analysis for the Behavioral Sciences, revised ed. Academic Press, New York.
83. Odone, A. and Odone, M. 1989. Lorenzo's oil. J. Pediatr. Neurosci. 5:55.
84. Rizzo, W. B., Leshner, R. T., Odone, A., Dammann, A. L., Craft, D. A., Jensen, M. E., Jennings, S. S., Davis, S., Jaitly, R., and Sgro, J. A. 1989. Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology 39:1415-1422.
85. Rizzo, W. B., Avigan, J., Chemke, J., and Schulman, J. D. 1984. Adrenoleukodystrophy: very-long-chain fatty acid metabolism in fibroblasts. Neurology 34:163-169.
86. Bourre, J. M., Daudu, O., and Baumann, N. 1976. Nervonic acid biosynthesis by emcyl-CoA elongation in normal and quaking mouse brain microsomes. Elongation of other unsaturated fatty acyl-CoAs (mono and poly-unsaturated). Biochim. Biophys. Acta 424:1-7.
87. Van Duyn, M. A., Moser, A. E., Brown, F. R. 3., Sacktor, N., Liu, A., and Moser, H. W. 1984. The design of a diet restricted in saturated very long-chain fatty acids: therapeutic application in adrenoleukodystrophy. Am. J. Clin. Nutr. 40:277-284.
88. Rizzo, W. B., Watkins, P. A., Phillips, M. W., Cranin, D., Campbell, B., and Avigan, J. 1986. Adrenoleukodystrophy: oleic acid lowers fibroblast saturated C22-26 fatty acids. Neurology 36:357-361.
89. Moser, A. B., Borel, J., Odone, A., Naidu, S., Cornblath, D., Sanders, D. B., and Moser, H. W. 1987. A new dietary therapy for adrenoleukodystrophy: biochemical and preliminary clinical results in 36 patients. Ann. Neurol. 21:240-249.
90. Bickel, H., Gerrard, J., and Hickman, E. M. 1953. Influence of phenylalanine intake on phenylketonuria. Lancet 2:812-813.
91. Moser, H. W., Aubourg, P., Cornblath, D., Borel, J., Wu, Y.-W., Bergin, A., and Naidu, S. M. A. B. 1991. Therapy for X-linked adrenoleukodystrophy. Pages 111-129, in Desnick, R. J. (ed.), Treatment of Genetic Disease. Churchill Livingstone, New York.
92. Meinert, C. L. 1996. Clinical Trials Dictionary. Terminology and Usage Recommendations. The Johns Hopkins Center for Clinical Trials.
93. Aubourg, P., Adamsbaum, C., Lavallard-Rousseau, M. C., Rocchiccioli, F., Cartier, N., Jambaque, I., Jakobezak, C., Lemaitre, A., Boureau, F., Wolf, C., et al. 1993. A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy. N. Engl. J. Med. 329:745-752.
94. Kaplan, P. W., Tusa, R. J., Shankroff, J., Heller, J., and Moser, H. W. 1993. Visual evoked potentials in adrenoleukodystrophy: a trial with glycerol trioleate and Lorenzo oil. Ann. Neurol. 34:169-174.
95. Rizzo, W. B., Leshner, R. T., Odone, A., Craft, D. A., Jennings, S. S., Jaitly, R., et al. 1990. X-linked adrenoleukodystrophy: biochemical and clinical efficacy of dietary erucic acid therapy. Pages 149-162, in Uziel, G., Wanders, R. J. A., and Cappa, M. E. (eds.) Adrenoleukodystrophy and other peroxisomal disorders. Excerpta Medica, Amsterdam.
96. Uziel, G., Bertini, E., Bardelli, P., Rimoldi, M., and Gambetti, M. 1991. Experience on therapy of adrenoleukodystrophy and adrenomyeloneuropathy. Dev. Neurosci. 13:274-279.
97. van Geel, B. M., Assies, J., Haverkort, E. B., Koelman, J. H., Verbeeten, B. Jr, Wanders, R. J., and Barth, P. G. 1999. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil". J. Neurol. Neurosurg. Psychiatry 67:290-299.
98. Restuccia, D., Di Lazzaro, V., Valeriani, M., Oliviero, A., Le Pera, D., Barba, C., Cappa, M., Bertini, E., Di Capua, M., and Tonali, P. 1999. Neurophysiologic follow-up of long-term dietary treatment in adult-onset adrenoleukodystrophy. Neurology 52:810-816.
99. Rasmussen, M., Moser, A. B., Borel, J., Khangoora, S., and Moser, H. W. 1994. Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's oil). Neurochem. Res. 19:1073-1082.
100. Asano, J., Suzuki, Y., Yajima, S., Inoue, K., Shimozawa, N., Kondo, N., Murase, M., and Orii, T. 1994. Effects of erucic acid therapy on Japanese patients with X-linked adrenoleukodystrophy. Brain Dev. 16:454-158.
101. Poulos, A., Gibson, R., Sharp, P., Beckman, K., and Grattan-Smith, P. 1994. Very-long-chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo's oil. Ann. Neurol. 36:741-746.
102. Moser, H. W. 1993. Lorenzo oil therapy for adrenoleukodystrophy: a prematurely amplified hope. Ann. Neurol. 34:121-122.
103. Moser, H. W., Raymond, G. V., Koehler, W., Sokolowski, P., Hanefeld, F., Korenke G. C., Green, A., Loes, D. J., Hunneman, D. H., Jones, R. O., Lu, S-E., Uziel, G., Giros Blasco, M. L., and Roels, F. 2003. Evaluation of the preventive effect of glyceryl trioleate-trierucate (Lorenzo's oil) therapy in X-linked adrenoleukodystrophy: results of two concurrent trials. In Roels, F., Baes, M., and de Bie, S. (eds), Peroxisomal disorders and regulation of genes, Kluwer Academic, New York.
104. Loes, D. J., Hite, S., Moser, H., Stillman, A. E., Shapiro, E., Lockman, L., Latchaw, R. E., and Krivit, W. 1994. Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am. J. Neuroradiol. 15:1761-1766.
105. Loes, D. J., Fatemi, A., Melhem, E. R., Gupte, N., Bezman, L., Moser, H. W., and Raymond, G. V. 2003. Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. Neurology (in press).
106. Melhem, E. R., Loes, D. J., Georgiades, C. S., Raymond, G. V., and Moser, H. W. 2000. X-linked adrenoleukodystrophy: the role of contrast-enhanced MR imaging in predicting disease progression. AJNR Am. J. Neuroradiol. 21:839-844.
107. Eichler, F. S., Itoh, R., Barker, P. B., Mori, S., Garrett, E. S., van Zijl, P. C., Moser, H. W., Raymond, G. V., and Melhem, E. R. 2002. Proton MR spectroscopic and diffusion tensor brain MR imaging in X-linked adrenoleukodystrophy: initial experience. Radiology 225:245-252.
108. Tsuji, S., Sano, T., Ariga, T., and Miyatake, T. 1981. Increased synthesis of hexacosanoic acid (C23:0) by cultured skin fibroblasts from patients with adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN). J. Biochem. (Tokyo) 90:1233-1236.
109. Kumar, A. J., Kohler, W., Kruse, B., Naidu, S., Bergin, A., Edwin, D., and Moser, H. W. 1995. MR findings in adult-onset adrenoleukodystrophy. AJNR Am. J. Neuroradiol. 16:1227-1237.
110. Fazekas, F., Ropele, S., Enzinger, C., Seifert, T., and Strasser-Fuchs, S. 2002. Quantitative magnetization transfer imaging of pre-lesional white-matter changes in multiple sclerosis. Mult. Scler. 8:479-184.
111. Moser, H. W. and Borel, J. 1995. Dietary management of X-linked adrenoleukodystrophy. Annu. Rev. Nutr. 15:379-397.
112. 1994. The lipid handbook. Pages 97-100 and 118-121, in Gunstone, F. D., Harwood, J. L., and Padley, F. B. (eds), Chapman & Hall Chemical Data Base, London.
113. Cutter, G. R., Baier, M. L., Rudick, R. A., Cookfair, D. L., Fischer, J. S., Petkau, J., Syndulko, K., Weinshenker, B. G., Antel, J. P., Confavreux, C., Ellison, G. W., Lublin, F., Miller, A. E., Rao, S. M., Reingold, S., Thompson, A., and Willoughby, E. 1999. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122(Pt 5):871-882.
114. Spilker, E. 1990. Quality of life assessments in clinical trials. Raven Press, New York.
115. Moser, A. B., Jones, D. S., Raymond, G. V., and Moser, H. W. 1999. Plasma and red blood cell fatty acids in peroxisomal disorders. Neurochem. Res. 24:187-197.